After NPC cells were treated with class I HDAC inhibitor MS-275 and class II HDAC inhibitor LMK-235, the results showed that MS-275 could inhibit the expression of ACSL4 (Fig. S2C). The gene discussed is HDAC9; the disease is nasopharyngeal carcinoma.